House Rx, a San Francisco, CA-based health technology platform focused on improving affordability and patient access to specialty medications, secured $25m in Series A financing.
The round, which brought total funding raised to date to $30m, was led by Bessemer Venture Partners with participation from First Round Capital, Character.vc, and 1984.vc.
The company plans on using the funds to invest in its technology platform, scaling its pharmacy operations, and continue investments in its technology platform.
Led by Ogi Kavazovic, CEO, Tesh Khullar, President, and Denali Cahoon, PharmD, Chief Pharmacy & Operating Officer, House Rx provides a technology platform and pharmacy service which enable specialty practices to offer medically-integrated dispensing, which means patients can receive both their physician and pharmacy care from one team, collaborating on a unified technology platform. The technology platform allows prescribers and pharmacists to work together through one integrated system. Built-in analytics allow for continuous improvement in the quality and efficiency of care.
Since it launched in March 2021, House Rx has partnered with four medical specialty practices and 30 prescribers in California and Washington. The specialty medical practices that have already partnered with House Rx include Care Oncology Center, California; Sarcoma Oncology, California; Arthritis Northwest Washington; and Northwest Medical Specialties, Washington.
The company has more than 30 employees currently, which include software engineers and pharmacist operations.